Alprazolam is a widely prescribed sedative and antidepressant benzodiazepine (BDZ) drug which belongs to the class of anxiolytic, sedative and hypnotic anticonvulsants. It is believed that alprazolam (ALP) is more fairly safe and it rapidly reduces the symptoms of anxiety through the control of the central nervous system (CNS) excitability by a selective and potent enhancement of inhibitory gammaamino butyric acid (GABA) mediated neurotransmission. Accelerated photochemical stability of alprazolam was performed under several conditions. The study involved the evaluation of the photostability of Alprazolam in active mater, in PVC/Aluminum blister packet (BPT) or without blister packet tablets (WBPT). The evaluation of the stability was performed using special stability test chambers at 60% controlled humidity, temperature and UV irradiation. The High-Performance Liquid Chromatography (HPLC) was used to analyze the content of the Alprazolam before and after UV irradiation. The obtained results for the short term photostability study do not show any significant degradation of this molecule by the UV irradiation in active mater and this holds true for the BPT or WBPT, independent of the Alprazolam content (0.25 or 0.50 mg).

1. S. J. Marin, R. Coles, M. Merrell, and G. A. McMillin, “Quantitation of benzodiazepines in urine, serum, plasma, and meconium by LC-MS-MS,” J. Anal. Toxicol., vol. 32, no. 7, pp. 491–498, 2008.
   DOI: 10.1093/jat/32.7.491
   PMid: 18713517
2. S. Karampela, I. Vardakou, I. Papoutsis, A. Dona, C. Spiliopoulou, S. Athanaselis, and C. Pistos, “Direct urine analysis for the identification and quantification of selected benzodiazepines for toxicology screening,” J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., vol. 902, pp. 42–46, 2012.
   DOI: 10.1016/j.jchromb.2012.06.012
   PMid: 22790390
3. G. Ngwa, D. Fritch, K. Blum, and G. Newland, “Simultaneous analysis of 14 benzodiazepines in oral fluid by solid-phase extraction and LC-MS-MS,” J. Anal. Toxicol., vol. 31, no. 7, pp. 369–376, 2007.
   DOI: 10.1093/jat/31.7.369
   PMid: 17725884
4. D. J. Greenblatt and C. E. Wright, “Clinical pharmacokinetics of alprazolam. Therapeutic implications,” Clin. Pharmacokinet., vol. 24, no. 6, pp. 453–471, 1993.
   DOI: 10.2165/00003088-199324060-00003
   PMid: 8513649
5. A. Mohd, A. A. Parwaz Khan, S. Bano, and K. S. Siddiqi, “UV-absorption and fluorimetric methods for the determination of alprazolam in pharmaceutical formulation,” Arab. J. Chem., vol. 6, no. 4, pp. 369–378, 2013.
   DOI: 10.1016/j.arabjc.2010.10.013
6. U. K. Chhalotiya, N. M. Patel, D. A. Shah, F. A. Mehta, and K. K. Bhatt, “Thin-layer chromatography method for the simultaneous quantification and stability testing of alprazolam and mebeverine in their combined pharmaceutical dosage form,” J. Taibah Univ. Sci., vol. 11, no. 1, pp. 66-75, Jan. 2017.
   DOI: 10.1016/j.jtusci.2015.06.012
7. K. M. Höld, D. J. Crouch, D. G. Wilkins, D. E. Rollins, and R. A. Maes, “Detection of alprazolam in hair by negative ion chemical ionization mass spectrometry,” Forensic Sci. Int., vol. 84, no. 1–3, pp. 201–209, 1997.
   DOI: 10.1016/S0379-0738(96)02063-4
8. O. Quintela, P. López, A. M. Bermejo, and M. López-Rivadulla, “Determination of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and alprazolam in human plasma by liquid chromatography-electrospray ionization mass spectrometry,” J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., vol. 834, no. 1–2, pp. 188–194, 2006.
   DOI: 10.1016/j.jchromb.2006.02.013
   PMid: 16517229
9. A. Allqvist, A. Wennerholm, J.-O. Svensson, and R. A. Mirghani, “Simultaneous quantification of alprazolam, 4- and alpha-hydroxyalprazolam in plasma samples using liquid chromatography mass spectrometry,” J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., vol. 814, no. 1, pp. 127–131, 2005.
   DOI: 10.1016/j.jchromb.2004.10.012
   PMid: 15607716
10. D. Di Corcia, S. Lisi, V. Pirro, E. Gerace, A. Salomone, and M. Vincenti, “Determination of pharmaceutical and illicit drugs in oral fluid by ultra-high performance liquid chromatography-tandem mass spectrometry,” J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., vol. 927, pp. 133–141, 2013.
    DOI: 10.1016/j.jchromb.2013.01.025
    PMid: 23433923
11. I. I. Papoutsis, S. A. Athanaselis, P. D. Nikolaou, C. M. Pistos, C. A. Spiliopoulou, and C. P. Maravelias, “Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology,” J. Pharm. Biomed. Anal., vol. 52, no. 4, pp. 609–614, 2010.
    DOI: 10.1016/j.jpba.2010.01.027
    PMid: 20172681
12. M. Blessy, R. D. Patel, P. N. Prajapati, and Y. K. Agrawal, “Development of forced degradation and stability indicating studies of drugs—A review,” J. Pharm. Anal., vol. 4, no. 3, pp. 159–165, 2014.
    DOI: 10.1016/j.jpha.2013.09.003
13. H. H. Tønnesen, “Formulation and stability testing of photolabile drugs,” Int. J. Pharm., vol. 225, no. 1–2, pp. 1–14, 2001.
    DOI: 10.1016/S0378-5173(01)00746-3